Barchart.com's Chart of the Day - Audentes Therapeutics
Related Stocks
 BOLD - Audentes Therapeutics Inc
SymLastChgPct
BOLD38.24-3.15-7.61%
The Chart of the Day belongs to Audentes Therapeutics (BOLD).  I found the biomedical stock by using Barchart to sort the Russell 3000 Index stock first by the highest Weighted Alpha, then I used the Flipchart feature to review the cahrts for consistent price appreciation.  Since the Trend Spotter signaled a buy on 1/11 the stock gained 4.78%.

Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California.

BOLD

Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

  • Weighted Alpha 174.58+
  • 80% technical buy signals 
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 6 new highs and up 28.15% in the last month
  • Relative Strength Index 63.97%
  • Technical support level at 36.17
  • Recently traded at 37.79 with a 50 day moving average of 29.69

Fundamental factors:

  • Market Cap $1.12 billion
  • Wall Street analysts haven't really giving good guidance on their expections for Revenue and Earnings
  • Despite their confusion Wall Street analysts gave 7 strong buy and 2 hold recommendations on the stock
  • The individual investors following the stock on Motley Fool voted 14 to 2 that the stock will beat the market